HIV Comorbidities and Treatment Side Effects
For 'Silver Tsunami' With HIV, New Hope For Healthy Aging
The New York Times, Sept. 10, 2023
People with H.I.V. are achieving the once unthinkable: a steady march into older age. But beginning around age 50, many people HIV face a host of health problems, from heart disease and diabetes to social isolation and cognitive decline. And so the medical research community, which some three decades ago developed lifesaving drugs to keep the virus at bay, is now hunting for new ways to keep older people with HIV healthier.
The New York Times, Sept. 10, 2023
People with H.I.V. are achieving the once unthinkable: a steady march into older age. But beginning around age 50, many people HIV face a host of health problems, from heart disease and diabetes to social isolation and cognitive decline. And so the medical research community, which some three decades ago developed lifesaving drugs to keep the virus at bay, is now hunting for new ways to keep older people with HIV healthier.
25 Years of HIV Research
POZ, July 2019
To mark POZ magazine's 25th anniversary: a review of the extra-ordinary achievements on the part of HIV scientists since 1994. The ever-refined collective mastery they have gained over the virus during this period represents one of the greatest achievements of human ingenuity.
POZ, July 2019
To mark POZ magazine's 25th anniversary: a review of the extra-ordinary achievements on the part of HIV scientists since 1994. The ever-refined collective mastery they have gained over the virus during this period represents one of the greatest achievements of human ingenuity.
Attention HIV-Positive Smokers: This Article Could Save Your Life
POZ, April 2018
HIV likely serves only to amplify smoking’s existing harms and vice versa. People with well-treated HIV perhaps double their risk of death by smoking, lose more years of life to the habit than to the virus and ultimately are more likely to die of smoking-related diseases than they are of causes related to the virus.
POZ, April 2018
HIV likely serves only to amplify smoking’s existing harms and vice versa. People with well-treated HIV perhaps double their risk of death by smoking, lose more years of life to the habit than to the virus and ultimately are more likely to die of smoking-related diseases than they are of causes related to the virus.
An Exciting Act II for the Study That Proved Treating HIV Early Is Best
POZ, February 2018
The scientists behind the global START study recently won a new funding stream from the the National Institutes for Health to continue following the large population of participants for another four years, through 2021.
POZ, February 2018
The scientists behind the global START study recently won a new funding stream from the the National Institutes for Health to continue following the large population of participants for another four years, through 2021.
"Should People With HIV Take a Statin?"
(POZ, February 2017)
Even when people living with HIV have a fully suppressed viral load, they still have a 50 to 100 percent greater risk of heart disease compared with the general population. Statins, the commonly prescribed class of drugs used to lower cholesterol and reduce the risk of CVD and death among the general population, may have the power to strike at some of the root causes of heart disease in people with HIV.
(POZ, February 2017)
Even when people living with HIV have a fully suppressed viral load, they still have a 50 to 100 percent greater risk of heart disease compared with the general population. Statins, the commonly prescribed class of drugs used to lower cholesterol and reduce the risk of CVD and death among the general population, may have the power to strike at some of the root causes of heart disease in people with HIV.
|
“A Gut Feeling.” (POZ, June 2015) How to deal with gastrointestinal problems, whether from the effects of the HIV or side effects from antiretrovirals. |
"Getting to the Heart of the Matter." (POZ, Oct. 2015) HIV raises the risk of heart disease. What can you do to lower that risk?
|
“Facing Facts: Dealing With Lipodys-trophy.” (POZ, July 2013) a significant proportion of the HIV population still suffers from the disfiguring loss or gain of fat in key areas of their bodies.
|
“Braving Cognitive Decline: Can People With HIV Fight Back?” (POZ, May 2013) The science behind the dispropor-tionate rates of cognitive decline among people living with HIV.
|
“The War on Cancer.” (POZ, March 2013) With AIDS-defining illnesses fading into the wings, a new health challenge for people living with HIV has moved toward center stage.
|
- POZ, Nov. 2015: "'HIV Is Like Diabetes'? Or So They Say." How much sense does the common comparison between HIV and diabetes actually make?
- POZ, Sept. 2015: "How People With HIV Can Combat Their Raised Risk of Cancer."
- POZ, June 2013: “Long Wait For HIV Diarrhea Drug Inspires Lawsuit.” Even after receiving priority review from the Food and Drug Administration, Fulyzaq, the first drug to treat diarrhea related to HIV meds, has been slow to market. A lawsuit by the biotech firm that developed Fulyzaq accuses its pharma partner of impeding the drug's progress, possibly on purpose.
- HIV Plus, Nov. 2004: “About Face.” Treating lipodystrophy and lipoatrophy, disfiguring side effects of some HIV meds.